The Level of Estrogen and Progesterone Receptor Immunoreactivity Correlates With Time to Disease Recurrence in Hormone Receptor-Positive Breast Cancer

被引：0
|
作者：
Winner, Megan [1 ]
Rosman, Martin [2 ]
Mylander, Charles [2 ]
Jackson, Rubie Sue [2 ]
Pozo, Marcos [1 ]
Umbricht, Christopher [3 ]
Tafra, Lorraine [2 ]
机构：
[1] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA
[2] Anne Arundel Med Ctr, Annapolis, MD USA
[3] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
来源：
ANNALS OF SURGICAL ONCOLOGY | 2016年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
0235
引用
收藏
页码：171 / 172
页数：2
相关论文
共 50 条
  • [31] Impact of progesterone receptor status on response to neoadjuvant chemotherapy in estrogen receptor-positive breast cancer patients
    Boland, Michael R.
    Ryan, Eanna J.
    Nugent, Timothy
    Gilroy, Darina
    Kelly, Michael E.
    Kennedy, John
    Maguire, Aoife
    Alazawi, Dhafir
    Boyle, Terence J.
    Connolly, Elizabeth M.
    JOURNAL OF SURGICAL ONCOLOGY, 2020, 122 (05) : 861 - 868
  • [32] Lost but Not Least-Novel Insights into Progesterone Receptor Loss in Estrogen Receptor-Positive Breast Cancer
    Kunc, Michal
    Popeda, Marta
    Biernat, Wojciech
    Senkus, Elzbieta
    CANCERS, 2021, 13 (19)
  • [33] The Clinicopathologic Characteristics and Clinical Outcomes of Estrogen Receptor-Negative and Progesterone Receptor-Positive Breast Cancer
    Kang, S.
    Jeon, Y.
    Kim, C.
    Cho, Y.
    Lee, S.
    CANCER RESEARCH, 2009, 69 (24) : 724S - 725S
  • [34] Disparities in Hormone Receptor-Positive Breast Cancer
    Ogayo, Esther R.
    Mittendorf, Elizabeth A.
    Kantor, Olga
    CURRENT BREAST CANCER REPORTS, 2024, 16 (01) : 106 - 115
  • [35] Palbociclib for hormone receptor-positive breast cancer
    Harding, Emilia
    LANCET ONCOLOGY, 2015, 16 (07): : E318 - E318
  • [36] Disparities in Hormone Receptor-Positive Breast Cancer
    Esther R. Ogayo
    Elizabeth A. Mittendorf
    Olga Kantor
    Current Breast Cancer Reports, 2024, 16 : 106 - 115
  • [37] Progesterone receptor levels are associated with time to aromatase inhibitor treatment failure in estrogen receptor-positive advanced breast cancer.
    Cristofanilli, M.
    De Giorgi, U.
    Rohren, E.
    Ueno, N. T.
    Miller, C.
    Doyle, G., V
    Jackson, S.
    Andreopoulou, E.
    Handy, B. C.
    Reuben, J. M.
    Hortobagyi, G. N.
    Macapinlac, H. A.
    Fritsche, H. A.
    Valero, V.
    CANCER RESEARCH, 2009, 69 (02) : 362S - 362S
  • [38] RB in breast cancer: Differential effects in estrogen receptor-positive and estrogen receptor-negative disease
    Musgrove, Elizabeth A.
    Sutherland, Robert L.
    CELL CYCLE, 2010, 9 (23) : 4607 - 4607
  • [39] Preventing late recurrence in hormone receptor-positive early breast cancer: a review
    Battisti, Nicolo Matteo Luca
    Smith, Ian E.
    EUROPEAN JOURNAL OF CANCER, 2022, 172 : 53 - 64
  • [40] A PROMISING ALTERNATIVE: NEOADJUVANT ENDOCRINE THERAPY IN ESTROGEN AND PROGESTERONE RECEPTOR-POSITIVE BREAST CANCER
    Malik, H.
    Pham, C.
    Garcia, A.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2022, 70 (02) : 556 - 557
12345